2022 - Research.com Best Female Scientist Award
Her scientific interests lie mostly in Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Amyloidosis. Her Internal medicine and Transplantation, Survival rate, Hematology, Dexamethasone and Survival analysis investigations all form part of her Internal medicine research activities. Her Transplantation research integrates issues from Plasma cell dyscrasia, Total body irradiation, Stem cell, POEMS syndrome and Organomegaly.
Her research integrates issues of Monoclonal gammopathy of undetermined significance and Pathology in her study of Multiple myeloma. Her biological study spans a wide range of topics, including Pomalidomide, Neutropenia, Immunology, Hazard ratio and Myeloma protein. Her Amyloidosis study integrates concerns from other disciplines, such as AL amyloidosis, Immunoglobulin Light-chain Amyloidosis, Hematologic Response, Nephrotic syndrome and Primary systemic amyloidosis.
Martha Q. Lacy focuses on Internal medicine, Multiple myeloma, Surgery, Gastroenterology and Oncology. Her work in Transplantation, Amyloidosis, Lenalidomide, Autologous stem-cell transplantation and Dexamethasone is related to Internal medicine. The study incorporates disciplines such as Survival analysis and Bone marrow, Pathology in addition to Multiple myeloma.
Her studies deal with areas such as Cohort and Primary systemic amyloidosis as well as Surgery. Her Gastroenterology research is multidisciplinary, relying on both Survival rate, Progression-free survival, Retrospective cohort study and Hazard ratio. Martha Q. Lacy interconnects Hematology, Newly diagnosed and Clinical trial in the investigation of issues within Oncology.
Martha Q. Lacy spends much of her time researching Internal medicine, Multiple myeloma, Oncology, Gastroenterology and AL amyloidosis. Her study in the field of Lenalidomide also crosses realms of In patient. She works mostly in the field of Oncology, limiting it down to concerns involving Waldenstrom macroglobulinemia and, occasionally, Rituximab.
Her research in Gastroenterology intersects with topics in Progression-free survival, Overall survival, Survival rate, Hazard ratio and Stage. Her AL amyloidosis study integrates concerns from other disciplines, such as Proteinuria and Melphalan. To a larger extent, she studies Surgery with the aim of understanding Transplantation.
Martha Q. Lacy mostly deals with Internal medicine, Multiple myeloma, Gastroenterology, AL amyloidosis and Amyloidosis. Internal medicine is closely attributed to Oncology in her study. Her Multiple myeloma research integrates issues from Stage, Newly diagnosed, Survival analysis and Hazard ratio.
Martha Q. Lacy has included themes like Odds ratio, Waldenstrom macroglobulinemia, Multivariate analysis, Cyclophosphamide and Kidney in her Gastroenterology study. The various areas that Martha Q. Lacy examines in her AL amyloidosis study include Survival rate, Cardiology, Proteinuria and Urology. Her studies in Transplantation integrate themes in fields like Stem cell and Lenalidomide.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
POEMS syndrome: definitions and long-term outcome.
Angela Dispenzieri;Robert A. Kyle;Martha Q. Lacy;S. Vincent Rajkumar.
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy.
Lancet Oncology (2013)
Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
Shaji K. Kumar;Joseph R. Mikhael;Francis K. Buadi;David Dingli.
Mayo Clinic Proceedings (2009)
Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
Angela Dispenzieri;Morie A. Gertz;Robert A. Kyle;Martha Q. Lacy.
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma.
Luis F. Porrata;Morie A. Gertz;David J. Inwards;Mark R. Litzow.
Clinical course of patients with relapsed multiple myeloma.
Shaji K. Kumar;Terry M. Therneau;Morie A. Gertz;Martha Q. Lacy.
Mayo Clinic proceedings (2004)
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
Paul G. Richardson;David S. Siegel;Ravi Vij;Craig C. Hofmeister.
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis.
Angela Dispenzieri;Martha Q. Lacy;Steven R. Zeldenrust;Suzanne R. Hayman.
Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma
Martha Q. Lacy;Angela Dispenzieri;Morie A. Gertz;Philip R. Greipp.
Mayo Clinic Proceedings (2006)
Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma.
C S Debes-Marun;G W Dewald;S Bryant;E Picken.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: